World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
49516
World Ranking
7544
National Ranking
3936

Fernando Cabanillas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Fernando Cabanillas sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 495 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Fernando Cabanillas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Fernando Cabanillas sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 102 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Fernando Cabanillas is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of Medicine, with a specific focus on oncology, pathology, infectious diseases, and immunology.

The scientist's work covers several subfields, including:

  • Pathology and Forensic Medicine
  • Oncology
  • Immunology
  • Infectious Diseases
  • Neurology

Central topics in their research include:

  • Lymphoma Diagnosis and Treatment
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cutaneous lymphoproliferative disorders research
  • T-cell and Retrovirus Studies

Among the frequently encountered publication venues for Fernando Cabanillas are:

  • Hematological Oncology
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood
  • The Lancet

Frequent coauthors collaborating with this researcher include:

  • Marek Trněný
  • Davide Rossi
  • Kensei Tobinai
  • Richard Tsang
  • Jürgen Westermann

Notable recent papers authored or coauthored by Fernando Cabanillas are:

  • "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," 2023, Journal of Clinical Oncology
  • "Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma," 2024, Journal of Clinical Oncology
  • "Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19," 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • "Home-based management of COVID-19 by identification of low-risk features," 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • "Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone," 2020, Blood

Best Publications

  • A predictive model for aggressive non-Hodgkin's lymphoma

    M. A. Shipp;D. P. Harrington;J. R. Anderson;J. O. Armitage

  • Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    B D Cheson;S J Horning;B Coiffier;M A Shipp

  • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

    P McLaughlin;A J Grillo-López;B K Link;R Levy

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • Non-Hodgkin's Lymphoma in 90 Homosexual Men: Relation to Generalized Lymphadenopathy and the Acquired Immunodeficiency Syndrome

    John L. Ziegler;Jay A. Beckstead;Paul A. Volberding;Donald I. Abrams

  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

    T. Philip;James Olen Armitage;G. Spitzer;F. Chauvin

  • Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

    WS Velasquez;F Cabanillas;P Salvador;P McLaughlin

  • High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

    Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio

  • Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

    Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro

  • ESHAP--an Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-year Follow-Up Study

    W. S. Velasquez;P. McLaughlin;Susan L Tucker;Fredrick B Hagemeister

  • Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification

    Ming Sheng Lee;Kun Sang Chang;Fernando Cabanillas;Emil J. Freireich

  • The Clinical Behavior of Localized and Multicentric Castleman Disease

    Juan Herrada;Fernando Cabanillas;Lawrence Rice;John Manning

  • Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

    Issa F. Khouri;Rima M. Saliba;Sergio A. Giralt;Ming Sheng Lee

  • Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

    I F Khouri;J Romaguera;H Kantarjian;J L Palmer

  • Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

    Koen van Besien;Chul S. Ha;Sandy Murphy;Peter McLaughlin

  • IMVP-16: An Effective Regimen for Patients With Lymphoma Who Have Relapsed After Initial Combination Chemotherapy

    Fernando Cabanillas;Fredrick B. Hagemeister;Gerald P. Bodey;Emil J. Freireich

  • Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

    Peter McLaughlin;Fredrick B. Hagemeister;Jorge E. Romaguera;Andreas H. Sarris

  • Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Jorge Cortes;Susan O'Brien;Sherry Pierce

Frequent Co-Authors

Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
James D. Cox
James D. Cox The University of Texas MD Anderson Cancer Center
Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Susan L. Tucker
Susan L. Tucker The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medicine but exploring alternative pathways or looking to branch out in the healthcare field? There are several online degrees and fast-track programs that offer flexibility and quicker entry into rewarding healthcare careers.

For those who want to start working in patient care sooner, fast track lpn programs online can help you become a Licensed Practical Nurse in less time than traditional routes. If you already have a nursing background and wish to specialize in mental health, the fastest psychiatric nurse practitioner program options online are worth considering. These programs prepare you for advanced roles with greater responsibility and earning potential.

Not all health professions require direct patient care. If you’re interested in the administrative side of healthcare, you can explore the cheapest online health science degree for entry-level administration or focus on leadership roles by considering the cheapest mha online programs for your graduate studies.

These options provide cost-effective and accelerated alternatives for students seeking flexibility or a nontraditional route into the healthcare sector.

Best Scientists Citing Fernando Cabanillas

Trending Scientists

Recently Published Articles